Why the study?
While DOACs are supported for expanding indications, key clinical scenarios remain where emerging literature continues to support warfarin as the preferred oral anticoagulant.
This review highlights specific clinical scenarios where warfarin remains the preferred oral anticoagulant despite the expanding use of DOACs.
Clinicians may retain warfarin in select scenarios; extends prior syntheses but leaves comparative RCTs open.
New evidence continues to support new indications and conditions in which DOACs may be appropriate to use for anticoagulation. There are key clinical scenarios, however, in which emerging literature continues to support warfarin as the preferred anticoagulant.
No takes yet. Share an insight, caveat, or question.
Wadsworth et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: